Quabodepistat

MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

Quabodepistat

CAS No. : 1883747-71-4

MCE 国际站：Quabodepistat

产品活性：Quabodepistat (OPC-167832) 是一种有效的口服活性 dprE1 抑制剂，其>IC₅₀ 为 0.258 μM。Quabodepistat 具有抗结核活性，可用于由结核分枝杆菌引起的结核病的相关研究。

研究领域：Anti-infection

作用靶点：Bacterial

In Vitro: Quabodepistat (OPC-167832) exhibits very low MICs against laboratory strains of?M. tuberculosis?H37Rv (MIC: 0.0005 μg/ml) and Kurono (MIC: 0.0005 μg/ml) and strains with monoresistance to rifampin (RIF), isoniazid (INH), ethambutol (EMB), streptomycin (STR), and pyrazinamide (PZA) (MIC: 0.00024-0.001 μg/ml). However, Quabodepistat has minimal or no activity against standard strains of nonmycobacterial aerobic and anaerobic bacteria.
The IC₉₀ values of Quabodepistat against intracellular M. tuberculosis strains H37Rv and Kurono are 0.0048 and 0.0027?μg/ml, respectively. Quabodepistat shows bactericidal activity against intracellular M. tuberculosis at a low concentration, and the bactericidal activity is saturated at concentrations of 0.004?μg/ml or higher.

In Vivo: Quabodepistat (OPC-167832) (oral administration; 0.625-10 mg/kg) exhibits a good pharmacokinetic??characteristic. The plasma reaches peak at 0.5 h to 1.0 h (t_max) and is eliminated with a half-life (t_1/2) of 1.3 h to 2.1 h?Quabodepistat distribution in the lungs is approximately 2 times higher than that in plasma, and the?C_max?and AUC_t of Quabodepistat in plasma and the lungs shows dose dependency.
Quabodepistat (oral administration; 0.625-10 mg/kg; 4?weeks) significantly reduces lung CFU compared to the vehicle group. The dose-dependent decrease of lung CFU is observed from 0.625?mg/kg to 2.5?mg/kg. In a?M. tuberculosis?Kurono-infected ICR female mice model. Quabodepistat combines with DMD, BDQ, or LVX via oral gavage exhibits significantly higher efficacies than each single agent alone.
.
Quabodepistat (oral gavage; 2.5?mg/kg; combination with DCMB; 12 weeks) demonstrates the most potent efficacy when compares with DC, DCB. The lung CFU count after 6 weeks of treatment is below the detection limit, and at the end of just 8 weeks of treatment, the bacteria in the lungs of all the evaluated mice had already been eradicate.

相关产品：Drug Repurposing Compound Library Plus  |  Clinical Compound Library Plus  |  Bioactive Compound Library Plus  |  Anti-Infection Compound Library  |  Immunology/Inflammation Compound Library  |  Clinical Compound Library  |  Drug Repurposing Compound Library  |  Antibacterial Compound Library  |  Orally Active Compound Library  |  Heterocyclic Compound Library  |  Anti-tuberculosis Compound Library  |  Rapamycin  |  Doxorubicin hydrochloride  |  Bafilomycin A1  |  Dexamethasone  |  Puromycin dihydrochloride  |  Dimethyl sulfoxide  |  Staurosporine  |  Actinomycin D  |  G-418 disulfate  |  Etoposide  |  5-Azacytidine  |  Nigericin sodium salt  |  Brefeldin A  |  Estradiol  |  CCCP  |  Ionomycin  |  Resveratrol  |  Hygromycin B  |  Tunicamycin  |  Mitomycin C  |  Everolimus  |  Doxycycline hyclate  |  Tacrolimus  |  Methotrexate  |  Neomycin sulfate  |  Acetaminophen  |  Streptozotocin  |  Anisomycin  |  Cholesterol

热门产品线：重组蛋白  |  化合物库  |  天然产物  |  荧光染料  |  PROTAC  |  同位素标记物

Trending products：Recombinant Proteins  |  Bioactive Screening Libraries  |  Natural Products  |  Dye Reagents  |  PROTAC  |  Isotope-Labeled Compounds